SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel program is the main focus, especially mature frontline melanoma results for lifileucel plus pembrolizumab and early sarcoma findings. Traders highlight durable melanoma responses as supportive of expansion into earlier treatment, while others caution that the cohorts are small and the sarcoma response rate eased as the sample grew.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A Nasdaq-futures rebound around the 1987 Black Monday anniversary is dominating discussion after a steep tech-led selloff, with big-tech earnings ahead. Traders are split on whether the bounce is a durable recovery or a short-covering rally that could fade, while AI-stock weakness and broader market risks remain concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A broad selloff in AI neocloud stocks, driven by worries about debt, financing costs, and whether rapid data-center spending can earn adequate returns, has weighed on Nebius alongside peers. Traders are divided: bears see further valuation pressure, while bulls argue Nebius is better positioned than more leveraged rivals and view the drop as an overdone sector-wide move.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after last weeks tech-led selloff has shifted the conversation to whether the bounce will hold, amid fears tied to the Black Monday anniversary. Bulls call it a relief rally or short squeeze and dismiss crash worries, while skeptics warn the move may fade; upcoming megacap earnings add to market focus.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Lingering concerns over weak guidance, slowing ad-spend growth, and competition in digital advertising are weighing on Trade Desk shares. Traders remain divided between expecting further declines until growth and execution improve and viewing the selloff and high short interest as a potential setup for a rebound.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention amid a sharp, extended semiconductor selloff, with traders questioning whether heavy AI infrastructure spending can deliver sufficient returns and citing inflation, rates, and competitive pressures as additional headwinds. The community is split between expecting an oversold bounce and warning that the pullback could deepen into a broader correction.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is drawing attention after a sharp selloff alongside Micron and other memory stocks, with traders debating whether the drop is a dip-buying opportunity or a sign of further downside. Some attribute the weakness to South Korean market moves and concerns around AI and memory demand, while others point to the funds leverage as amplifying its volatility.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The discussion centers on shifting leadership between the Magnificent Seven and semiconductors/AI infrastructure, with traders debating whether MAGS can resume leading after a pullback. Some see renewed mega-cap strength and breakout potential, while others point to recent weakness and worry that money is rotating elsewhere.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Iovance Biotherapeutics Names Noah Berkowitz CMO

(RTTNews) - Iovance Biotherapeutics (IOVA), a biotechnology company, on Thursday announced the appointment of Noah Berkowitz as Chief Medical Officer, effective September 30...

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026

Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump? 

Equity

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%. 

Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus

The 30-year Treasury yield topped 5.6% on Tuesday, its highest in more than 24 years, while New York Fed President John Williams said there's no "urgency" to raise rates.

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? 

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence. 


Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today

FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.read more...

These Stocks are Charging Higher as Traders Watch What Comes Next

The following are showing notable momentum today, with Kraig Biocraft Laboratories (OTCQB:KBLB), Iovance Biotherapeutics (NASDAQ:IOVA), Volato Group (NYSEAMERICAN:SOAR), Carnival Corporation (NYSE:CCL), Teads Holding (NASDAQ:TEAD), Quantum-Si (NASDAQ:QSI), and KALA Bio (NASDAQ:KALA) all posting gains and holding their moves as traders look toward the afternoon and tomorrow.

Iovance Biotherapeutics Stock Rises 33% After Raising FY26 Total Revenue Outlook

(RTTNews) - Shares of Iovance Biotherapeutics, Inc. (IOVA) are gaining about 33 percent on Tuesday morning after the company announced its decision to raise its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi and Prole...

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Investors are closely watching the upcoming ESMO data release, with eyes on frontline melanoma combo efficacy and sarcoma durability.

Sector-wide volatility driven by broader XBI weakness and macro pressures is temporarily impacting prices, despite robust company fundamentals.

Aggressive scaling to over 100 treatment centers reflects strong commercial demand as the therapy platform continues to mature.

Market attention is shifting toward Q4 lung data and the confirmatory Phase 3 trial as key indicators for long-term valuation.

Current Price	$13.62
Prev Close	$14.72
Open	$14.65
Dividend Yield	0.00%
50-Day Moving Average	$10.12
Beta	1.71
Avg. Volume	17.84M
PE Ratio	-18.88

52-Week High	$15.30
52-Week Low	$1.76
Market Capitalization	$6.17B
EPS (Annual)	-$1.09
Price to Book	8.38
Revenue Per Employee	$270,258.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

IOVA Fundamentals